Abstract
Amifostine is a first-line cytoprotective drug used to prevent radiotherapy-induced or chemotherapy-induced injuries. However, its mechanism of action is not well understood. In this study, freshly harvested bone marrow cells were treated with amifostine and analyzed with a series of mitochondrial indices. In vitro results showed that bone marrow cells treated with amifostine 0.5 h before irradiation (0.5 Gy) experienced several benefits, as compared to vehicle controls, including (1) reduced reactive oxygen species levels, which reduced the production of free radicals; (2) better preservation of mitochondria, as indicated by MitoTracker-positive staining and the increased intensity of staining; (3) reduced apoptosis, as demonstrated by Annexin V staining; and (4) a better proliferation rate, as illustrated by MTT assay. Our in vitro studies showed that amifostine-treated mice exhibited (1) higher ATP production; (2) reduced plasma IL-2 levels, suppressing the immune response triggered by radiotoxicity; and (3) enhanced radiation-induced production of granulocyte colony-stimulating factor. All of these processes benefit recovery from radiation-induced damage.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ozcan Arican G (2005) Cytoprotective effects of amifostine and cysteamine on cultured normal and tumor cells treated with paclitaxel in terms of mitotic index and 3H-thymidine labeling index. Cancer Chemother Pharmacol 56(2):221–229
Hensley ML, Hagerty KL, Kewalramani T et al (2009) American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 27(1):127–145
Kouvaris JR, Kouloulias VE, Vlahos LJ (2007) Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist 12(6):738–747
Culy CR, Spencer CM (2001) Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs 61(5):641–684
Capizzi RL, Scheffler BJ, Schein PS (1993) Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy. Cancer 72(11):3495–3501
Invitrogen (2009) Amplex red hydrogen peroxide/peroxidase assay kit. http://probes.invitrogen.com/media/pis/mp22188.pdf. Updated 26 June 2009. Accessed 01 May 2013
Invitrogen (2008) MitoTracker mitochondrion-selective probes. https://www.ipmc.cnrs.fr/fichiers/recherche/microscopie/Sondes/MitoGreen.pdf. Updated 29 Mar 2013. Accessed 01 May 2013
Pape H, Orth K, Heese A et al (2006) G-CSF during large field radiotherapy reduces bone marrow recovery capacity. Eur J Med Res 11(8):322–328
Riley PA (1994) Free radicals in biology: oxidative stress and the effects of ionizing radiation. Int J Radiat Biol 65(1):27–33
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this paper
Cite this paper
Lv, W. et al. (2013). Amifostine Acts Upon Mitochondria to Stimulate Growth of Bone Marrow and Regulate Cytokines. In: Van Huffel, S., Naulaers, G., Caicedo, A., Bruley, D.F., Harrison, D.K. (eds) Oxygen Transport to Tissue XXXV. Advances in Experimental Medicine and Biology, vol 789. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7411-1_27
Download citation
DOI: https://doi.org/10.1007/978-1-4614-7411-1_27
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-7256-8
Online ISBN: 978-1-4614-7411-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)